

BRAIN DISEASE SITE COMMITTEE MEETING VIRTUAL SPRING MEETING AGENDA

Friday, April 29th, 2022, 11:00 am EDT – 12:30 pm EDT
Chairs : Dr. David Roberge & Dr. Marshall Pitz
Senior Investigator: Dr Chris O'Callaghan

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

1. To cite and analyze recent results of clinical studies conducted by or in collaboration with the Canadian Cancer Trials Group relevant to CNS malignancies
2. To summarize recent developments in molecular biology and therapeutics research, as related to CNS malignancies
3. To interpret and address, through clinical and translational research, the disease burden associated with CNS malignancies in Canada.
4. To interpret and apply new clinical trial methodologies in the field of clinical research in CNS malignancies

11:00 am	Welcome & Introductions	Dr. D. Roberge Dr. M. Pitz
15 min	CCTG CNS Platform Trial Concept – Proposal and Discussion	Dr. M. Pitz Dr. D. Roberge
15 min	McGill Phase II Newly Diagnosed GBM Trial Presentation and Phase III Concept Proposal	Dr. G. Shenouda
10 min	2021 – 2026 CCS Major Program Grant Renewal Application: Brain Disease Site Feedback	Dr. W. Mason Dr. C. O'Callaghan
5 min	Brief Update on Still Active and Recently Closed Trials: <ul style="list-style-type: none"> • CE.8 (EORTC 1709 BTG MIRAGE) • CEC.1 (EORTC 26053-22054) • CEC.6 (N0577) 	Dr. W. Mason
10 min	CE.7: A Phase III Trial of Stereotactic Radiosurgery compared with Hippocampal Avoidant Whole Brain Radiotherapy (HA-WBRT) plus Memantine for 5-15 Brain Metastases	Dr. D. Roberge
10 min	CEC.7 (A071801): Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS for Resected Metastatic Brain Disease	Dr. D. Roberge
10 min	NCTN Update	Dr. W. Mason
10 min	IND Committee Update & Collaboration Opportunities	Dr. M. Pitz